Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.3
-55.2 (-1.72%)

 

  • STI Straits Times Index
    3,166.3
    -55.2 (-1.72%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,512.2
    -5.4 (-0.35%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,080.5
    -659.6 (-2.67%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,564.1
    -20.1 (-0.56%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,751.6
    -747.7 (-2.53%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,561.6
    -137.8 (-2.06%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,737.0M
  • Value: 1,744.7M
  • Rise: 72
  • Fall: 305
  • Unch: 381

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
HGH0.021-0.004
Sembcorp Marine0.084-0.001
Medtecs Intl0.400+0.110
Genting Sing0.795-0.035
ThaiBev0.695-0.020
QT Vascular0.006-0.002
Singtel2.440-0.030
Tritech0.022+0.001
Suntec Reit1.550-0.020
Hatten Land0.061-

World Indices

World Indices
Name Last Change
Nasdaq 15,491.7 -353.6
HSI 24,080.5 -659.6
HSCEI 8,576.1 -233.7
Jakarta 6,561.6 -137.8
Nikkei 225 28,751.6 -747.7
SSE Comp 3,564.1 -20.1
Shanghai A 3,735.3 -21.1
Shanghai B 281.0 -1.2
KOSPI 2,936.4 -43.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

AC IMMUNE SA AC IMMUNE SA
Updated on 26 Nov 2021 (End of trading day)
Last (USD): 5.170 Change: -0.180 High: 5.410 Remarks: -
Change (%): -3.36 Low: 5.050

Company Background

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.90803 Trailing EPS (USD) b -1.07807 NAV (USD) c 2.6444
PE a - Trailing PE d - Price / NAV c 1.9551
Dividend Yield (%) e - Cash In Hand (USD) f 1.3808 Issued & Paid-up Shares g 72,652,700
Piotroski F Score 1 Market Cap (M) 375.614 Free Float (%) 48.6
Return on Equity (ROE) (%) h n.m. Revenue Growth (%) TTM i -93.646
Net Earnings Growth (%) j -21.306 Net Debt/Equity k Net Cash
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted based on Profit Attributable To Shareholders.
  2. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  3. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  4. Based on latest Full Year results announcement, adjusted for the current number of shares.
  5. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  6. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  7. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 06 May 2021. Please click here for more information.
  8. Calculated based on Net Earnings / (Shareholders' Equity - Other Share Capital)
  9. Calculated based on (Current Year Revenue - Last Year Revenue) / Last Year Revenue
  10. Calculated based on (Current Year Earnings - Last Year Earnings) / Last Year Earnings
  11. Calculated based on (Long Term Debt + Short Term Debt - Cash and Short Term Investments)/(Shareholders' Equity - Other Share Capital)

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.300
-5.48 %
10 Days --0.730
-12.37 %
20 Days --1.270
-19.72 %
Medium Term Return 3 Months --1.770
-25.50 %
6 Months --0.920
-15.11 %
1 Year --0.400
-7.18 %
Long Term Return 2 Years --2.830
-35.38 %
3 Years --5.950
-53.51 %
5 Years --6.330
-55.04 %
Annualised Return Annualised --
-14.78 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference AC IMMUNE SA NASDAQ 375.614 - - 1.9551 -
Industry Pharmaceuticals: Major NASDAQ 2,183.565 86.513 91.614 2.7892 0.027
Local Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 175,301.248 54.850 119.171 4.4108 -
Local Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 122,056.515 8.695 17.625 1.6276 -
Local Peer ROYALTY PHARMA PLC NASDAQ 25,434.519 26.086 32.491 4.3905 0.458
Local Peer REPLIGEN CORP NASDAQ 15,813.064 263.876 133.018 9.2190 -
Local Peer VIATRIS INC NASDAQ 15,419.722 - - 0.7294 -
Local Peer EVOTEC SE SPON ADS EACH REP 0.50 ORD SHS NASDAQ 8,325.054 1,167.815 28.260 7.2363 -
Local Peer CUREVAC NV NASDAQ 8,254.105 - - - -
Local Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,180.151 - - 7.1040 -
Local Peer LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS NASDAQ 7,834.816 - - - -
Local Peer HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS NASDAQ 6,082.200 - - 6.1762 -
Local Peer I MAB SPON ADS EACH REP 2.3 ORD SHS NASDAQ 4,932.615 72.298 72.298 5.7326 -
Local Peer CEREVEL THERAPEUTICS HLDGS INC NASDAQ 4,732.165 - - 7.5224 -
Other Local Peers ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), OPKO HEALTH INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), ICOSAVAX INC (NASDAQ), GH RESEARCH PLC (NASDAQ), PROCAPS GROUP S.A. (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), GENERATION BIO CO (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), 2SEVENTY BIO INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), PETIQ INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), ESSA PHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), XILIO THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), PHARVARIS NV (NASDAQ), PROVENTION BIO INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), TRICIDA INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), EVOLUS INC (NASDAQ), COMPASS THERAPEUTICS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), CLENE INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), 89BIO INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), DURECT CORP (NASDAQ), IMMUNIC INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), ATHENEX INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), MUSTANG BIO INC (NASDAQ), OBSEVA SA (NASDAQ), INOZYME PHARMA INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), JOURNEY MEDICAL CORPORATION (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ENTERA BIO LTD (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), PROPHASE LABS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), BIOFRONTERA INC (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), IMARA INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), GALECTO INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), MANNATECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP